 - Primary outcome immunogenicity is measured by antibody levels against HPV serotype 16 18 over time. We consider HPV vaccination to be immunogenic at antibody titers above the cutoffs 20 and 24 mMUml for HPV 16 and 18, respectively; or at a 2 fold increase in antibody levels against both serotypes. The antibody levels will be measured prior to vaccination, and after 3,7 and 12 months. 